Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avecho Biotechnology Limited ( (AU:AVE) ) just unveiled an announcement.
Avecho Biotechnology is advancing its TPM-based drug delivery platform, focusing on human and animal health applications that enhance oral, dermal and transdermal absorption, with its main product a cannabidiol soft-gel capsule aimed at improving CBD uptake for insomnia patients.
The company has released a presentation for an investor webinar on the upcoming interim analysis of its pivotal Phase III trial of TPM-enhanced CBD capsules for insomnia, a large, multi-centre study designed to meet Australian, U.S. and European regulatory standards and potentially support over-the-counter registration in Australia, where Avecho could secure first-mover advantage in a growing CBD sleep market.
Insomnia affects a significant share of the global population and imposes substantial economic costs, particularly in Australia where sleep health has been flagged as a national priority, underscoring the commercial and clinical importance of Avecho’s trial program in the broader sleep economy and sleep aids market.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian biopharmaceutical company developing human and animal health products based on its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery technology. Derived from vitamin E, TPM is designed to improve the solubility and absorption of drugs and nutrients, with Avecho’s lead asset being a TPM-enhanced cannabidiol soft-gel capsule in Phase III development for insomnia treatment.
Average Trading Volume: 10,220,109
Technical Sentiment Signal: Sell
Current Market Cap: A$49.8M
For an in-depth examination of AVE stock, go to TipRanks’ Overview page.